What is Belviq?
Belviq is prescribed to adults who are overweight or obese and have serious health issues due to their weight. This medication works best when combined with a low-calorie diet and regular exercise. It is classified as a serotonin receptor agonist drug. It functions by making people feel fuller after eating less food.
Working Mechanism of medicine?
The Food and Drug Administration (FDA) has approved Belviq for use in adults with a body mass index (BMI) of 30 or above or those with a BMI of at least 27. They also have at least one weight-related disease, such as hypertension, diabetes, or high cholesterol.
It’s meant to trick your body into thinking it’s full even though you’ve eaten less. The therapeutic medication stimulates serotonin receptors in the brain. Serotonin receptors influence hunger. When they send the message to your body that it’s complete, you’ll naturally eat less food and drop pounds.
In addition to a low-calorie diet and exercise routine, the prescribing literature for Belviq recommends that consumers take one 10 mg pill twice a day. The Food and Medicine Administration recommends that the drug be used indefinitely to help patients maintain a healthy weight. Women who are pregnant or nursing should no longer take Belviq.
Belviq Adverse Effects
The following are some of the most common side effects of this medicine:
Patients who do not have diabetes:
headache \sdizziness \sfatigue
symptoms of nausea, vomiting diarrhea
As it pertains to those who have diabetes:
Insufficient sugar in the blood (hypoglycemia)
Weakness in the head and the spine
This is not a comprehensive catalog of the possible unwanted effects of this medication.
Use with caution if you’re taking a monoamine oxidase inhibitor (MAOI), a linezolid derivative, a selective serotonin reuptake inhibitor (SSRI), a tricyclic antidepressant (TCA), bupropion, lithium, tramadol, tryptophan, St. John’s wort, an antipsychotic, a dopamine antagonist, or a PDE-5 inhibitor. Accelerates the metabolism of CYP2D6 substrates like dextromethorphan. Taking two or more tablets at once that are both highly effective agonists for the serotonin 2B (S2B) receptors increases the risk of cardiac valvulopathy (e.g., cabergoline). No longer a research focus: concomitant insulin. There are additional drugs that can help, such as Regeneron Retard.